| Multiple Myeloma |
1 |
1 |
| Biologic Therapy |
0 |
0.99 |
| CAR-T |
0 |
0.86 |
| Receptors |
0 |
0.52 |
| Refractory |
0 |
0.52 |
| T-Cell Receptor |
0 |
0.44 |
| Antigens |
0 |
0.41 |
| Proteasome Inhibitor |
0 |
0.31 |
| Dentistry and Oral Health |
0 |
0.26 |
| Otolaryngology |
0 |
0.26 |
| Dysgeusia |
0 |
0.21 |
| Immunomodulator |
0 |
0.21 |
| Toxicology |
0 |
0.15 |
| Anemia |
0 |
0.1 |
| Antibody Drug Conjugates |
0 |
0.1 |
| Blood |
0 |
0.1 |
| Cancer |
0 |
0.1 |
| Clinical Research |
0 |
0.1 |
| Healthcare and Medical Technology |
0 |
0.1 |
| Hematology |
0 |
0.1 |
| Hodgkin Lymphoma |
0 |
0.1 |
| Neurotoxicity |
0 |
0.1 |
| Neutropenia |
0 |
0.1 |
| New York |
0 |
0.1 |
| Opportunistic Infection |
0 |
0.1 |
| Plasma |
0 |
0.1 |
| Stem Cell Research and Therapy |
0 |
0.1 |
| Thrombocytopenia |
0 |
0.1 |
| Tissue |
0 |
0.1 |